Drug Trial Radar · NCT07392450
A Study of TAK-755 in Adults With Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
222
Planned (sponsor's estimate)
Start
May 17, 2026
Primary completion
Dec 6, 2027
Study completion Dec 6, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible. The main aim of this study is to check how safe TAK-755 is, and how well adults with AIS tolerate it. Other aims are to check how well TAK-755 helps participants to manage their everyday activities and to understand whether it helps reduce the seriousness of their stroke symptoms when compared to placebo. A placebo looks like TAK-755, but does not have any medicine in it, to make sure participants do not know which treatment they are taking. The participants will receive TAK-755 or placebo once; afterwards, their health will be monitored for about 3 months (90 days). All participants, regardless of their assignment to either TAK-755 or placebo, will receive the usual treatment for AIS as per the hospital's normal practice.
Conditions
- Acute Ischemic Stroke
Interventions
TAK-755Biological
TAK-755 IV infusion.
PlaceboOther
TAK-755 matching placebo IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and B: Percentage of Participants who Develop Symptomatic Intracranial Hemorrhage (sICH) as Defined by the Heidelberg Bleeding Classification SystemTime frame: Up to 120 hours of study drug administration
Locations
60 sites in 10 countries. Site status is shown where the registry gives one.
HonorHealth Neurology
Scottsdale, Arizona · Recruiting
University of Arizona
Tucson, Arizona · Not yet recruiting
University of California San Francisco
San Francisco, California · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Not yet recruiting
University at Buffalo
Buffalo, New York · Not yet recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Not yet recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Not yet recruiting
HCA Houston Healthcare - North Cypress
Cypress, Texas · Not yet recruiting
Neurology Consultants of Dallas, PA
Dallas, Texas · Not yet recruiting
Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman
Liège, Belgium · Not yet recruiting
Groupe sante CHC - Clinique du MontLegia
Liège, Belgium · Not yet recruiting
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium · Not yet recruiting
Universitair Ziekenhuis Gent (Belgium,Ghent)
Ghent, Oost-Vlaanderen, Belgium · Not yet recruiting
AZ Groeninge
Kortrijk, WVL, Belgium · Not yet recruiting
Porto Alegre Clinical Hospital (HCPA)
Porto Alegre, Rio Grande do Sul, Brazil · Not yet recruiting
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu
Botucatu, São Paulo, Brazil · Not yet recruiting
Universidade Estadual de Campinas (UNICAMP)
Campinas, São Paulo, Brazil · Not yet recruiting
Hospital Das Clinicas da Faculdade de Medicina de Ribeirao Preto - Universidade de Sao Paulo
Ribeirão Preto, São Paulo, Brazil · Not yet recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil · Not yet recruiting
Hospital Sao Paulo / Escola Paulista de Medicina da Universidade Federal de Sao Paulo (EPM/UNIFESP)
São Paulo, São Paulo, Brazil · Not yet recruiting
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Nanshi Hospital of Nanyang
Nanyang, Henan, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Liaocheng People's Hospital
Liaocheng, Shandong, China · Recruiting
Linyi People's Hospital
Linyi, Shandong, China · Recruiting
Sinopharm Tongmei General Hospital
Datong, Shanxi, China · Recruiting
Linfen Central Hospital
Linfen, Shanxi, China · Recruiting
CHU Bordeaux, CHU Pellegrin
Bordeaux, Aquitaine, France · Not yet recruiting
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Raymond-Poincare
Garches, IDF, France · Not yet recruiting
Bicetre Hospital
Le Kremlin-Bicêtre, IDF, France · Not yet recruiting
Groupe Hospitalier Bichat Claude Bernard
Paris, IDF, France · Not yet recruiting
Hopital Lariboisiere
Paris, IDF, France · Not yet recruiting
Charite Universitatsmedizin Berlin
Berlin, Germany · Not yet recruiting
Universitaetsklinikum Heidelberg (UKHD)
Heidelberg, Baden-Wurttemberg, Germany · Not yet recruiting
Universitaetsklinikum Tuebingen
Tübingen, Baden-Wurttemberg, Germany · Not yet recruiting
Klinikum Ernst von Bergmann
Potsdam, Brandenburg, Germany · Not yet recruiting
Goethe-Universitaet-Universitaetsmedizin Frankfurt-Zentrum der Neurologie und Neurochirurgie (ZNN)
Frankfurt am Main, Hesse, Germany · Not yet recruiting
Universitaetsmedizin Goettingen
Göttingen, Lower Saxony, Germany · Not yet recruiting
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.